Skip to content

Clinical study on the napex acupoint catgut embedding therapy combined with metoprolol tartrate tablet for prophylactic treatment of migraine without aura and brain fMRI mechanism

Clinical study on the napex acupoint catgut embedding therapy combined with metoprolol tartrate tablet for prophylactic treatment of migraine without aura and brain fMRI mechanism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000185
Enrollment
Unknown
Registered
2024-08-07
Start date
2024-08-15
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

Acupuncture group:napex acupoint catgut embedding therapy
Western medicine group:metoprolol tartrate tablet
Healthy control group:None
Acupuncture and medicine group:napex acupoint catgut embedding therapy combined with metoprolol tartrate tablet

Sponsors

Nanjing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Patients who met the diagnostic criteria for migraine without aura and had intermittent episodes at the time of initial treatment in this study; 2) In the range of 18 to 65 years, the course of disease is more than 6 months, the average headache attack is more than 2 times per month; 3) Did not receive preventive treatment of migraine including acupuncture and medicine in the past 1 month; 4) The patient voluntarily received the relevant preventive treatment and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Contraindications to the use of metoprolol, including but not limited to patients with symptomatic bradycardia or hypotension, atrioventricular block, morbid sinus syndrome, heart failure, acute myocardial infarction, cardiogenic shock, severe peripheral vascular disease with gangrene, treated with ß agonists, and allergic to any component or other metoprolol of ß blockers; 2) Organic lesions such as tumors, inflammation, and degenerative diseases; 3) Combined with severe neurological, cardiovascular, digestive, urinary, blood system, endocrine system diseases unrelated to migraine; 4) Pregnant and lactating women; 5) Serious mental illness, cognitive impairment so that the normal communication and diagnosis and treatment; 6) Have contraindications to MRI examination such as metal implants in the body and claustrophobia; 7) Have severe asymmetric head anatomical structure or clear lesions found in MRI examination.

Design outcomes

Primary

MeasureTime frame
the number of headache attack days;frequency of headache attacks;

Secondary

MeasureTime frame
headache severity;The Migraine-specific Quality of Life Questionnaire;Amplitude of Low Frequency Fluctuation,ALFF;improved response rate by 50%;

Countries

China

Contacts

Public ContactLamei Tao

Nanjing Hospital of Traditional Chinese Medicine

799258654@qq.com17768101781

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026